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Blood Transfusion: 
The Risks and Benefits 
Julia A. Frohlich MD 
As greater attention is focused on medical and legal risks of the 
transfusion process, physicians ordering a blood transfusion 
must advise their patients thoroughly and clearly of the potential 
risks involved. Physicians must explain clearly to patients that a 
zero-risk blood supply is impossible to achieve; patients must 
understand that all necessary steps practicable have been 
taken to ensure the safest possible supply. 
Introduction 
Blood transfusion is not a perfectly safe procedure; however, 
neither is omitting transfusion for a patient at risk of dying of 
anemia or bleeding.1 
A statement issued at the National Institutes of Health Con-
sensus Development Conference in June 1988 made this obser-
vation: "Transfusion is a lifesaving measure in the management 
of a variety of medical and surgical conditions ... For many 
patients, homologous red cell transfusion carries great benefits, 
permitting surgical procedures that would not otherwise be 
possible, and allowing medical therapies for patients who are or 
may become anemic." 2 
In her article "Explaining Benefits of Transfusion," Linda 
Stehling MD states, "The physician must ask, 'What is the goal 
of therapy?' ... The goal must be to benefit the patient in some 
way. The alternatives must also be considered."3 
Since several alternatives to transfusion are available, the 
patient should be given an explanation of both the positive and 
negative aspects of each as it relates to his or her particular 
situation. 
Areas of concern In transfusion 
Risk associated with transfusion can be either immediate or 
long-term and includes both immunologic and infectious dis-
ease consequences. Areas of particular concern that the physi-
cian should discuss with the patient are: 
• Hemolytic transfusion reactions ranging from fever and 
chills to death. 
• Transmission of infectious diseases such as hepatitis 
or AIDS. 
• Febrile reactions causing temporary increase in 
body temperature. 
• Immune problems ranging from urticaria to breathing 
difficulties or, on rare occasions, donor inability to accept 
homologous blood without becoming ill. 
Transfusion risk projection 
Many reports in medical literature now available assess the 
risk of transmission of infectious diseases by blood transfusion, 
in particular HIV. The projection of risk usually has been 
determined in one of 3 ways: 
• Actual cases of transfusion-transmitted AIDS 
(since mid-1985, when the test for HIV was applied to all 
donated blood). 
• Reports from investigative techniques such as polymerase 
chain reaction (PCR) and viral cultures of tested donor blood. 
• Studies projecting probable risks of infection based on 
epidemiologic models. 
Three techniques are involved in blood conservation: Reduc-
tion of blood loss both during surgery and for diagnostic pur-
poses; minimizing transfusion of blood and components, ac-
complished by hemodilution; and autologous blood transfusion. 
Actual case studies 
Risks of transfusion transmitted disease 
According to Roger Y. Dodd PhD, American Red Cross 
Holland Laboratories, "The safety of the blood supply continues 
to increase, not only as a result of major innovations such as the 
elimination of paid donations [in the 1970s] and the introduction 
of new tests [in the 1980s], but also because of incremental 
improvements in test sensitivity and refinements in the process 
of education donors and assessing their qualifications."4 
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In a six-year study of transfusion-transmitted hepatitis C in 
cardiac surgery patients, as reported in the New England Journal 
of Medicine, investigators at Johns Hopkins, Baylor, and St. 
Lukes in Houston found the incidence to have decreased mark-
edly (84%) since implementation of hepatitis C virus testing in 
May 1990.5 
The authors estimated the risk of transfusion-transmitted hepa-
titis C at 3 per 10,000 units transfused, based on finding 3 
seroconversions in 552 patients who received 9,916 units of blood 
that had been tested and were negative by the first generation 
HCV test. The risk is lower now with the improved sensitivity of 
the second generation test for HCV which has been in use by all 
U.S. blood banks since March 1992. 
In the same study (reported completely in the Annals of 
Internal Medicine, October 1, 1992) the risks of transfusion-
transmitted HIV -1 and HIV -1/2 from screened blood were found 
HAWAII MEDICAL JOURNAL. VOL. 53, JANUARY 1994 
20 
to be about one in 60,000 units transfused. A total of 11,532 
surgery patients were followed at the 3 institutions to determine 
the incidence of transfusion-transmitted disease. These patients 
had received 120,301 units of blood or blood components and 2 
of the patients were infected with HIV-1, for a risk of approxi-
mately 1 in 60,000 units of blood. The authors felt the current risk 
of transfusion-transmitted AIDS from blood that had tested 
negative for HIV is probably lower today because of improved 
sensitivity of the tests now in use, coupled with more effective 
exclusion of high risk donors. Both infected patients had been 
transfused prior to 1990. The seroconversion for HTL V -1/II was 
1 in 69,272 units. 
Another report of AIDS transmission from blood screened 
negative for antibody to HIV is found in the New England Journal 
of Medicine (May 28, 1992). The authors, from the Centers for 
Disease Control, describe results of investigating 158 reports that 
CDC had received of patients with transfusion-transmitted AIDS 
from negatively screened blood. 6 
In this investigation, 98 patients had completed follow-up, 14 
other cases had information that removed them from the study 
(eg, transfusion in a foreign country) and 47 cases are still open 
for further investigation. Of the 98 patients with a completed 
follow-up, only 15 had actually been exposed to HIV through the 
receipt of blood from donors who initially tested negative for HN 
antibody and were later confirmed to be infected with HIV. 
To date, no cases of transfusion-transmitted AIDS from blood 
tested for HN have been reported in Hawaii. 
Investigative techniques 
Another way to determine risk of transfusion-transmitted HN 
is to culture peripheral blood mononuclear cells and perform 
genetic amplification with PCR in fully screened HN -negative 
blood donors, seeking evidence of HIV. 
In a report published in New England Journal of Medicine 
(July 4, 1991) from the University of California-San Francisco 
and the Irwin Memorial Blood Center, HIV was found in one of 
76,500 donations that underwent culture and PCR in a 2-year 
period (November 1987 to December 1989). According to the 
authors, "Given the similarity between the rate of HIV-1 
seropositive donations in San Francisco to date (0.01%) and the 
rates in most other cities around the country, the risk we observed 
is probably comparable to that in other major metropolitan areas. 
It is noteworthy that our estimate lies within the confidence 
intervals of recent projections based on epidemiological models, 
as well as within the confidence intervals of a prospective follow-
up study of recipients of screened blood. Collectively these 
results put into perspective the low risk of HIV -I transmission by 
transfusion of fully screened blood." 7 
Epidemiologic model studies 
Dodd notes that an analysis of data on the infectivity of the last 
seronegative blood donation from donors who subsequently 
became positive suggests that the infectious-window period for 
HN is about 45 days and that the overall risk of infection is one 
in 225,000 units. He compares this figure to higher estimates of 
one in 60,000 based on isolation of HIV of seroconversion of 
recipients in locations where the prevalence of HIV is relatively 
-
high. Based on surveillance studies and efficiency of laboratory 
tests, he estimates the frequency of transfusion-transmitted hepa-
titis B at one in 200,000 units. 4 
Other rare infections, such as Yersinia enterocolitica, malaria, 
Babesia microti, and Trypanosoma cruzi, are reported rarely in 
the United States, with a risk of less than one in 1 million units. 
One author, Ira A. Shulman MD, notes that only 5 cases of 
transmission of such parasitic infections have occurred in one 
year in the United States out of more than 12 million units ofblood 
collected and transfused. 8 
Noninfectious adverse reactions to blood transfusion and their 
reported frequency are: Fever/chills, 1-in-50 to 1-in-1 00; urticaria, 
1-in-1 00; hemolytic transfusion reaction, 1 in 6,000; fatal hemolytic 
transfusion reaction, 1 in 100,000. 9 
Autologous donation-an overview 
In the quest for maximum safety in blood transfusion, a strong 
case exists for encouraging autologous donation as the optimal 
transfusion alternative. A recipient who serves as his or her own 
donor receives the safest possible transfusion in that the risks of 
transfusion-transmitted infection and alloimmunization are elimi-
nated. Patients who donate their own blood for use in their own 
elective surgery reduce their risk for immune reactions and 
infectious diseases associated with allogeneic transfusion. 10 
The Blood Bank of Hawaii has been providing autologous 
donation as a service to Hawaii patients since the 1970s and 
currently performs more than 100 procedures annually. A patient's 
blood is not drawn if the Blood Bank's medical director deter-
mines the procedure has potential to cause harm to the patient. 
Other health care institutions that provide autologous donation 
service include The Queen's Medical Center, Kaiser Permanente 
Medical Center, Kuakini Medical Center, St. Francis Medical 
Center, Maui Memorial Hospital, and Hilo Hospital. The number 
of procedures performed by these institutions ranges from more 
than 700 to fewer than 50 annually depending on hospital size and 
need. 
Eligibility criteria 
In general, a patient healthy enough to undergo a planned 
surgical procedure usually can tolerate phlebotomy. The patient 
must have a minimal hemoglobin level of 11 g/dl or a hematocrit 
of 34%, and the frequency of donation can be no more than every 
4 days to allow for equilibration of plasma volume. It is best to 
collect blood as far in advance of the intended date of surgery as 
possible to allm·: the patient's hematocrit to return to pre-dona-
tion levels, and patients are deferred from donating if any of the 
following conditions exists: 
• Severe hypertension 
• Cardiac symptoms such as angina or arrhythmia 
• Severe aortic stenosis 
• Recent myocardial infarction or active cardiac failure 
• Active infection 
• Positive test for HIV or HBsAg. 
Benefits of autologous donation 
According to Robert L. Thurer MD and Margot S. Kruskall 
MD in "Alternatives to Random-Donor Transfusion," "Autolo-
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gous donation can have very important benefits in the appropri-
ate patient population, since exposure to homologous blood 
usually can be reduced or eliminated. A second effect, possibly 
advantageous and deserving more study, is a higher hematocrit 
during surgery and hospitalization, due partly to the erythropoi-
etic stimulus of phlebotomy and partly to the greater likelihood 
that red cells will be given if autologous units are available."" 
Benefits of autologous transfusion for the donor-patient are 
numerous, and a physician should explain clearly to the patient 
that this procedure: 
• Eliminates transmission of infectious disease 
• Eliminates risk of alloimmunization to erythrocyte, 
leukocyte, platelet or protein antigens 
• Eliminates risk of hemolytic, febrile or allergic reactions due 
to alloantibodies 
• Eliminates risk of graft-versus-host reactions 
• Stimulates erythropoiesis by repeated preoperative 
phlebotomy 
• Reduces the quantity of homologous blood used in a given 
procedure. 
Risks of autologous donation 
The drawbacks to autologous donation are limited and for the 
most part of minor significance: 
• Potential exists for presurgical anemia or hypovolemia12 
• Potential exists for human error and mix-up of blood units 
prior to transfusion. 
Additionally, according to Thurer and Kruskall, "Collecting 
and transfusing autologous blood is unnecessary and inappro-
priate for those surgical procedures that seldom require transfu-
sion. Medical facilities and fiscal resources are strained when 
patients donate autologous blood that will not be used."13 
"The most important option [for the physician] is to do 
everything possible to make transfusion unnecessary, to elimi-
nate the transfusion experience ... The first question to be consid-
ered for any patient is, 'Is the transfusion necessary?"'" 
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